USPTO Patent Application: Psychedelics Combined with NMDA Receptor Agonists

ChangeBridge: Patent Apps - Pharma (A61K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260083759A1) detailing combinations of psychedelic drugs with NMDA receptor agonists for treating neuropsychiatric and neurologic disorders. The application was filed on August 29, 2023, and is scheduled for publication on March 26, 2026.

View original document View source feed page

What changed

This document is a USPTO patent application (US20260083759A1) concerning novel combinations of psychedelic drugs with NMDA receptor agonists. The application, filed on August 29, 2023, by inventors Bernard LERER and Uriel HERESCO, outlines compositions and methods for treating neurological and neuropsychiatric disorders such as schizophrenia, and for enhancing neuroplasticity. The patent is scheduled for publication on March 26, 2026.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on pharmaceutical companies or drug manufacturers. However, it signifies potential future intellectual property protection in the emerging field of psychedelic therapeutics, which may influence research and development strategies and market exclusivity for related treatments.

Source document (simplified)

← USPTO Patent Applications

Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders

Application US20260083759A1 Kind: A1 Mar 26, 2026

Inventors

Bernard LERER, Uriel HERESCO

Abstract

This invention provides in some aspects, combinations, compositions and kits comprising a psychedelic drug and an NMD A receptor agonist and applications and uses of same for treating, reducing the incidence of, reducing the severity of or improving a pathology of a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder, or for enhancing neuroplasticity in a subject with a neurologic disease or disorder, a neurocognitive disease or disorder, or a motor disease or disorder making use of the combinations, compositions and kits of this invention.

CPC Classifications

A61K 31/675 A61K 31/137 A61K 31/198 A61K 31/36 A61K 31/382 A61K 31/4045 A61K 31/42 A61K 31/4535 A61K 31/454 A61K 31/48 A61K 31/496 A61K 31/4985 A61K 31/519 A61K 31/5415 A61K 31/5513 A61K 31/553 A61K 31/554 A61P 25/18